arrhythmogenic early afterdepolarizations (EADs) characteristic of LQT2 myocytes under b-adrenergic stimulation. Parameters of Ca handling were measured in ventricular myocytes isolated from normal and LQT2 hearts using confocal Ca imaging and whole-cell patch clamp. Ca imaging revealed no LQT2-mediated changes in amplitude of Ca transients and SR Ca content under basal conditions. Experiments in saponin-permeabilized cells using SRentrapped low-affinity Ca indicator revealed enhanced RyR-mediated SR Ca leak and SERCA-mediated Ca uptake in LQT2 myocytes. Correspondingly, western blot analyses using phospho-specific antibodies showed that phosphorylation of both RyR and phospholamban is significantly higher in LQT2 CMs vs. controls at both PKA and CaMKII sites. In the presence of isoproterenol (50 nM) LQT2 CMs exhibited diminished Ca transient amplitudes and SR Ca content compared to controls. Stimulation of LQT2 CMs with isoproterenol resulted in prolongation of plateau of action potentials accompanied by aberrant Ca releases and phase 3 EADs, in contrast to controls. Importantly, preincubation of LQT2 CMs with CaMKII inhibitor KN93 (10 min, 500 nM) prevented ISO-mediated changes in AP duration, disturbances in Ca handling and EADs. Analysis of CaMKII activity revealed no differences between LQT2 and control heart tissues, while Western-blot analysis demonstrated 30% decrease in the abundance of catalytic subunit of protein phosphatase type 1 (PP1). These data suggest that hyperactive RyRs due to adaptive reduction in PP1 activity and thereby RyR hyperphosphorylation is a key contributor to enhanced triggered activity in hereditary LQT2 syndrome.
arrhythmogenic early afterdepolarizations (EADs) characteristic of LQT2 myocytes under b-adrenergic stimulation. Parameters of Ca handling were measured in ventricular myocytes isolated from normal and LQT2 hearts using confocal Ca imaging and whole-cell patch clamp. Ca imaging revealed no LQT2-mediated changes in amplitude of Ca transients and SR Ca content under basal conditions. Experiments in saponin-permeabilized cells using SRentrapped low-affinity Ca indicator revealed enhanced RyR-mediated SR Ca leak and SERCA-mediated Ca uptake in LQT2 myocytes. Correspondingly, western blot analyses using phospho-specific antibodies showed that phosphorylation of both RyR and phospholamban is significantly higher in LQT2 CMs vs. controls at both PKA and CaMKII sites. In the presence of isoproterenol (50 nM) LQT2 CMs exhibited diminished Ca transient amplitudes and SR Ca content compared to controls. Stimulation of LQT2 CMs with isoproterenol resulted in prolongation of plateau of action potentials accompanied by aberrant Ca releases and phase 3 EADs, in contrast to controls. Importantly, preincubation of LQT2 CMs with CaMKII inhibitor KN93 (10 min, 500 nM) prevented ISO-mediated changes in AP duration, disturbances in Ca handling and EADs. Analysis of CaMKII activity revealed no differences between LQT2 and control heart tissues, while Western-blot analysis demonstrated 30% decrease in the abundance of catalytic subunit of protein phosphatase type 1 (PP1). These data suggest that hyperactive RyRs due to adaptive reduction in PP1 activity and thereby RyR hyperphosphorylation is a key contributor to enhanced triggered activity in hereditary LQT2 syndrome.
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Rapid Calcium Modulation in Cells: Direct Intracellular Access using Nanostraws Alexander Xu 1 , Sally A. Kim 2 , Amin Aalipour 1 , Nicholas A. Melosh 1 . Intracellular calcium plays a role in a host of cellular functions ranging from synaptic transmission to gene expression. As a transient, short-range signaling molecule, calcium is often presented in complex signal patterns, including oscillations and bursts. The concerted action of pumps, channels, and buffers in conjunction with the ion-impermeable cell membrane tightly regulates these calcium signals spatially and temporally but simultaneously impedes our ability to study the action of calcium. Many techniques measure changes in intracellular calcium, providing insights into the specificity of these signal patterns, but fewer are capable of controlling calcium levels in cells. Patch clamp pipette access can be used to modulate calcium in small numbers of cells, but larger scale control often requires disruption of normal calcium signaling using drugs such as thapsigargin, in order to couple intracellular calcium to an external calcium signal. Here we present a new technology to rapidly modulate intracellular calcium. Using supported nanotubes called ''nanostraws,'' we demonstrate direct ionic delivery into cells. The dimensions of the nanostraws (~100 nm x 1 mm tall) allow them to spontaneously penetrate the cell, thereby allowing calcium to bypass the lipid membrane and its constituent calcium channels through the nanostraws. Calcium delivery is controlled by fluid flow, and intracellular calcium oscillations can be induced and modulated in amplitude and frequency. While previous studies have perturbed long-term cell behavior using nanostraws and similar systems, here we apply the technique to transient signaling by rapid intracellular calcium modulation and characterize the spatiotemporal delivery using calcium indicators (e.g. Fluo-4, GCaMP6). By circumventing the intrinsic calcium regulatory mechanisms, nanostraws provide direct access and the ability to mimic biological calcium oscillations, adding a new method for decoding the role of calcium signal patterns and their effects on downstream signaling. gene. F508del -deletion of a single phenylalanine residue at position 508 -is the most common lethal mutation found in CF patients. Fully synthesized F508del-CFTR is rapidly degraded in the endoplasmic reticulum due to F508del-induced misfolding, preventing proper transport of the protein to the epithelial cell membrane. In previous work, we have demonstrated that F508del facilitates partial unfolding and consequent aggregation of the first nucleotide-binding domain in human CFTR (hNBD1). This F508delfaciliated aggregation is likely a key contributor in F508del-CF pathogenesis. These findings established a foundation to develop a new high-throughput biophysical screen to identify compounds that directly bind to the hNBD1 domain to prevent the F508del-hNBD1 aggregation in vitro and thereby stabilize F508del-CFTR in vivo. We used computational protein engineering to construct an equivalently stable hNBD1 variant that reacts with a visible fluorophore exclusively at a single labeling site. Fluorescence self-quenching of this labeled domain upon unfolding/aggregation provides a robust assay for stabilizing compounds, and this assay gives a Z-factor 0.8 in high-throughput screening. We will describe thermodynamic and structural studies on compounds identified using this screen as well as progress in implementing an equivalent screen in models of full-length human CFTR. Our results demonstrate that thermodynamic stabilization of a protein via interaction of a small molecule at a site remote from a mutation can indirectly correct a genetic defect.
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Converting a Stimulatory ATP Binding Site to an Inhibitory One by the Disease-Associated Mutation, G551D Wen-Ying Lin, Kang-Yang Jih, Tzyh-Chang Hwang. University of Missouri, Columbia, MO, USA. G551D, the third most common pathogenic mutation in CF, exhibits an extremely low Po because ATP fails to increase its activity. Although VX-770 (Ivacaftor) improves the symptoms of patients carrying the G551D mutation, it is insufficient to completely rectify this gating abnormality. In excised inside-out patches, we found that VX-770 increases the ATPindependent Po of WT-CFTR by~9-fold, a magnitude very similar to the effect of VX-770 on G551D-CFTR (12.8 5 1.9 fold, n = 12), suggesting a common mechanism of action: VX-770 simply shifts the equilibrium of ATP-independent gating towards the open state. However, upon ATP removal VX-770-potentiated macroscopic G551D-CFTR currents increases initially bỹ 2-fold (1.65 5 0.48, n = 3), followed by a slow decay. Such a biphasic time course suggests two ATP binding sites with opposite effects and different affinities. We hypothesize that the G551D mutation converts the low-affinity ATPbinding site (i.e., site 2) to an inhibitory site, whereas the high-affinity site 1 remains stimulatory. This hypothesis predicts that lowering [ATP] could actually increase the G551D-CFTR current. Indeed, replacing 2 mM ATP with 20 mM ATP increases the current by~2-fold. To further test this idea, we mutated W401 and Y1219, two aromatic amino acids known to interact with ATP in site 1 and site 2 respectively. While ATP removal increases G551D/W401G currents by~2-fold (2.12 5 0.12, n = 8), a mono-phasic current decrease is seen with G551D/Y1219G-CFTR. However, the relaxation time constants for the current decay phase for G551D and G551D/Y1219 (41.8 5 1.0 s and 32.4 5 1.6 s respectively) are significantly longer than that of G551D/ W410G (28.8 5 0.5 s). These results point to a unique mechanism underlying CF pathogenesis by the G551D mutation.
adamantane cage reduced activity. Another showed that the adduct must be more than 2 carbons. Pre-exposing the virus to drug before inoculation showed inactivation and exposure-recovery of the virus on the~10-minute time scale. Resistance development is dramatically reduced. For selected compounds, 10 passages (~5 weeks) in the presence of drug were required before the 2009 H1N1 developed resistance. However, the mechanism of action is unclear. Liposome assays indicate direct block of S31N M2 (22-62). But 2009 H1N1 M2-transfected HEK cells are not blocked, either on the 2-or the 30-minute time scales. Yet, the revertant (N31S) is well blocked. Solid state NMR suggests that drugs bind to the S31N transmembrane peptide domain. The resistant strains developed in the presence of these drugs show no mutations in M2, but a few mutations in hemagglutinin. It is possible that these hydrophobic amines function partly by neutralizing the endosome. However, the virus pre-exposure results indicate a direct effect on the virus, not just on the endosome. The A/WSN/33 virus is not blocked by these drugs in cytopathic effect assays, but the revertant (N31S) is, indicating for A/WSN/33 that the M2-block is the key effect. In summary, resistance-invulnerable drugs for the 2009 H1N1 influenza A virus have been identified and the mechanism of action is yet to be defined.
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Dual Regulation of G Proteins and the G Protein-Activated Potassium Channels (GIRK) by Lithium Isabella Farhy Tselnicker 1 , Vladimir Tsemakhovich 1 , Ida Rishal 1 , Carmen W. Dessauer 2 , Nathan Dascal 1 . 1 Tel Aviv University School of Medicine, Tel Aviv, Israel, 2 University of Texas Health Science Center, Houston, TX, USA. Cellular targets of Li þ , such as glycogen synthase kinase 3b and G proteins, have been long implicated in bipolar disorder (BPD) etiology. However, recent genetic studies link BPD to other proteins, in particular ion channels. Li þ affects neuronal excitability, but the underlying mechanisms and the relevance to putative BPD targets are unknown. We discovered a novel, dual regulation of G proteingated K þ channels (GIRK) by Li þ , and determined the underlying molecular mechanisms. In hippocampal neurons, therapeutic doses of Li þ , 0.5-2 mM, increased GIRK basal current (I basal ) but attenuated neurotransmitter-evoked GIRK currents (I evoked ) mediated by G i/o -coupled G protein-coupled receptors (GPCRs). Molecular mechanisms of these regulations were studied with heterologously expressed GIRK1/2. In excised membrane patches, Li þ increased I basal but reduced GPCR-induced GIRK currents. Both regulations were membranedelimited and G protein-dependent, requiring both Ga and Gbg subunits. Li þ did not impair direct activation of GIRK by Gbg, suggesting that inhibition of I evoked results from a Li þ action on Ga, probably through inhibition of GTP-GDP exchange. In direct binding studies, Li þ promoted GPCR-independent dissociation of Ga i GDP from Gbg by a Mg 2þ -independent mechanism. This previously unknown Li þ action on G proteins explains the second effect of Li þ , the enhancement of GIRK's I basal . The dual effect of Li þ on GIRK may profoundly regulate inhibitory effects of neurotransmitters acting via GIRKs. Our findings link between Li þ , neuronal excitability, and both cellular and genetic targets of BPD: GPCRs, G proteins and ion channels.
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The Microglial K D Channels Kv1.3 and KCa3.1 as Potential Therapeutic Targets for Ischemic Stroke Heike Wulff 1 , Yi-Je Chen 1 , Paul D. Jenkins 1 , Hai Nguyen 1 , April L. Garing 1 , Ralf Köhler 2 . 1 Pharmacology, University of California, Davis, CA, USA, 2 University H. Miguel Servet, IACS and ARAID, Zaragoza, Spain. Activated microglia significantly contribute to the secondary inflammatory damage in ischemic stroke and therefore constitute attractive targets for post-infarct intervention. Microglia express the voltage-gated Kv1.3 and the calciumactivated KCa3.1 channels, both of which have been reported to be involved in microglia mediated neuronal killing, oxidative burst and inflammatory cytokine production. However, most of these experiments have been performed with cultured neonatal microglia and it has always been questioned whether these cultures accurately reflect the K þ channel expression of activated microglia in adult brain. Following intrahippocampal LPS injection or middle cerebral artery occlusion (MCAO) with 7 days of reperfusion we observed Kv1.3 and KCa3.1 immunoreactivity on activated microglia in mouse brain. In both conditions we further detected currents exhibiting the biophysical and pharmacological properties of Kv1.3 and KCa3.1 on microglia immediately following isolated with CD11b-magnetic beads. Channel expression was significantly higher than on microglia isolated from control brains. We next investigated the effect of genetic deletion and pharmacological blockade of KCa3.1 on the reperfusion injury following ischemic stroke using reversible MCAO as a model. KCa3.1 -/mice and wild-type mice treated with the KCa3.1 blocker TRAM-34 exhibited significantly smaller infarct areas and improved neuronal survival and motor coordination in neurological deficit test on day-7 after MCAO. Kv1.3 blockade with PAP-1 exhibited similar beneficial effects in wild-type mice but did not further reduce infarct area or improve neurological deficit in KCa3.1 -/mice. In male Wistar rats combined blockade of both Kv1.3 and KCa3.1 with PAP-1 and TRAM-34 also did not further reduce infarct area compared to treatment with either TRAM-34 or PAP-1 alone suggesting that blockade of one microglial K þ channel is sufficient to improve outcomes in ischemic stroke. Supported by RO1 GM076063 from the National Institute of Health. Epi4K Consortium, Nature 501:217-221, 2013) recently reported discovery of several de novo mutations in genes encoding ion channels, neurotransmitter receptors and other proteins that may explain severe, early onset childhood epilepsy. One intriguing variant was found in KCNB1, encoding K V 2.1. Although K V 2.1 is a potassium channel involved in repolarization of neuronal action potentials, it has not previously been associated with epilepsy. The reported variant (T374I) was heterozygous and affects a highly conserved residue within the K V 2.1 ion selectivity filter 5 amino acids N-terminal to the GYG motif. We performed heterologous expression of wildtype (WT) and mutant K V 2.1 channels and used whole-cell patch clamp recording to define the functional consequences of the mutation and to infer the pathophysiology of the epilepsy. Wild-type or mutant K V 2.1 channels were transiently expressed under control of the CMV promoter in CHO cells. Expression of channel subunits was confirmed by co-expression of a fluorescent protein encoded by the same plasmid. Cells expressing homomeric WT-K V 2.1 exhibited large outward currents with rapid voltage-dependent activation and slow inactivation. By contrast, cells expressing homomeric K V 2.1-T374I exhibited no outward or inward current. Our findings suggest that this mutation impairs ion permeation and confers a loss-of-function as the molecular basis for epilepsy. Further studies will evaluate the impact of mutant subunits on formation of functional heteromultimeric channels to explore possible dominant-negative behavior. The human voltage-gated proton channel (hHv1) is a transmembrane protein responsible for selective proton permeation across cell membranes in nasal mucosa, sperm, and white blood cells. Its pathological states include male infertility, allergies, and diseases such as cystic fibrosis, asthma, and lupus. Its involvement in ischemic stroke and invasiveness of breast cancer cells has substantiated hHv1 as a therapeutic target for drug designs for which require the understanding of hHv1 structure and proton conduction mechanism. We recently constructed and validated a homology model (Kulleperuma et al., 2013) of hHv1 characterized by the presence of a salt bridge between anionic D112 and cationic R208 side chains in the narrow region of the hydrated pore. Thanks to the pairing of these and other charged residues in ionic networks, the distribution of charged and polar residues in the wild-type channel is a priori compatible with permeation of either cations or anions. However, a staticfield electrostatic barrier opposing cation movement arises in neutral mutants of residue D112, consistent with the observation that these mutants are selective to anions (Musset et al., 2011) . Our recent experiments show that proton selectivity is restored in double mutant D112V/V116D, while D112S and D112V/D116S are anion-selective and D112V does not conduct ions. Atomistic molecular dynamics simulations of these mutants in lipid bilayers show that their structures differ in the organization of ionic side chains in the external vestibule and suggest that, consistent with the above analysis, the distribution
2189-Plat

2190-Plat
